2023. Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s196. DOI:https://doi.org/10.25251/skin.7.supp.196.